Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc.

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Sagimet Biosciences, Inc. Class A today and set a price target of $28.00. Nash cov...

Canaccord Genuity Remains a Buy on Sagimet Biosciences, Inc. Class A (SGMT)

In a report released today, Kaveri Pohlman from Clear Street reiterated a Buy rating on Sagimet Biosciences, Inc. Class A, with a price target of $...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SGMT	$6.67	-8.25%	1.51M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SGMT	$6.67	-8.3%	1.51M
3
4
5
6

SGMT

SGMT

No Data Available

Get Sagimet Biosciences Inc. Data in Excel

Get Sagimet Biosciences Inc. Data in Excel